Literature DB >> 19009629

A retrospective review of the outcome of plasma exchange and aggressive medical therapy in antibody mediated rejection of renal allografts: a single center experience.

Wisam Al-Badr1, Dorina Kallogjeri, Kamel Madaraty, Dana Oliver, Bahar Bastani, Brenda J Grossman.   

Abstract

UNLABELLED: Antibody-mediated rejection (AMR) has been recognized as a major cause of renal allograft loss. Protocols using plasma exchange (PE) to reverse rejection have mixed results.
METHODS: A retrospective chart review was performed to determine the clinical response to PE inpatients with AMR of renal allograft. A good response to treatment was defined as a decline in serum creatinine (SCr) to within 25% above the prerejection value or discontinuation of dialysis with a SCr <2 mg/dl within 3 months of discharge from the hospital and disappearance of donor-specific alloantibodies (DSA).
RESULTS: Twenty-two patients, treated with PE for biopsy proven AMR with or without acute-cellular rejection (ACR), were included in the study. Sixty-four percent of patients had concurrent AMR and ACR. Fifty-two percent of all patients had a good response to antirejection therapy, whereas 63% of patients with only AMR and 46% of patients with both AMR and ACR had a good response. Good response to PE did not correlate with the number of plasma volumes exchanged (P = 0.09), but correlated with a shorter period from transplantation to the rejection episode (P = 0.002).
CONCLUSION: Only a shorter interval between transplantation and the acute rejection episode correlated with a good response to PE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19009629     DOI: 10.1002/jca.20181

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  1 in total

1.  Successful Salvage Treatment of Resistant Acute Antibody-Mediated Kidney Transplant Rejection with Eculizumab.

Authors:  Saif A Khan; Dawood Al-Riyami; Yasser W Al-Mula Abed; Saja Mohammed; Marwa Al-Riyami; Nabil M Al-Lawati
Journal:  Sultan Qaboos Univ Med J       Date:  2016-08-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.